JELA PHARM LIMITEDActive

Company number 08477790Private limited companyIncorporated 2013

Key figures

£802,881+41.1%
Net assets 2024/25
+1,416.8%
Average annual growth 2019/20–2024/25
0250 k500 k750 k1 m2019/202020/212021/222022/232023/242024/25

Like most small UK companies, JELA PHARM LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
01 m2 m3 m2019/202020/212021/222022/232023/242024/25
Filed accounts2019/20–2024/25
2020/212021/222022/232023/242024/25
Cash at bank and in hand167,869126,208109,936213,005302,165
Total assets274,394271,249374,5721,809,1522,154,817
Total liabilities209,652186,113251,2621,239,9601,351,936
Net assets / total equity86,943110,316234,059569,192802,881
Average number of employees4772020

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: JELA PHARM LIMITED

Company

JELA PHARM LIMITED is a private limited company registered with Companies House under company number 08477790. It was incorporated on 8 Apr 2013. Its status is active. The registered office is in Oadby (LE2). Its nature of business (SIC 2007) is manufacture of pharmaceutical preparations (21200).

Accounts

The latest accounts in the database are for 2024/25 (period ending 30 Apr 2025); the company files small company accounts (filleted). Net assets were £802,881, up 41.1% on the previous year. Cash at bank and in hand was £302,165. Total assets were £2,154,817 and total liabilities £1,351,936. The company had an average of 20 employees. Figures are available for 6 financial years (2019/20–2024/25).

Control and charges

One person with significant control is registered. 4 of 7 registered charges are outstanding.

Filing deadlines

The next accounts are due by 30 Apr 2027. The next confirmation statement is due by 26 Jul 2027.